- The COARID-19 vaccine, which was developed by AstraZeneca, can be 95% effective in preventing the virus, CEO Pascal Soriot reported on Sunday weekend over weekend.
- Soriot also said that he thinks the vaccine may protect against a new strain of COVID-19 that is more contagious than the original and is spreading throughout the UK.
- AstraZeneca submitted vaccine data to UK health regulators last week and emergency use authorization could be imminent with a roll-out to UK citizens early next week.
- Shares of AstraZeneca jumped 4% in Monday trading.
- See AstraZeneca Business here.
According to The Telegraph, the COVID-19 vaccine developed by AstraZeneca can receive emergency usage authorization from UK regulators by Monday or Tuesday this week, with the rollout of the vaccine to UK citizens.
AstraZeneca submitted its COVID-19 vaccine data to UK regulators on 23 December, and CEO Pascal Soriot believes the data will show the efficacy of its vaccines in preventing COVID-19 infection, as Pizer and BioNtech at 95% is.
“We feel that we have figured out the winning formula and how to achieve efficacy, after two doses, with everyone there,” Soriot told the Sunday Times newspaper.
Data for the vaccine will be published “at some point”, Soriot told the paper.
Shares of AstraZeneca jumped 4% to $ 50.28 in Monday trading.
Read more: ‘It could be a roaring 20s that will end badly’: An equity major who oversees more than $ 7 billion shares his investment book and major predictions for 2021 and beyond.
Soriot said he believes AstraZeneca’s COVID-19 vaccine will protect against a new strain of the virus, which is considered more contagious than the original strain and is spreading to the UK.
“We think the vaccine against the new strain should remain effective”, Soriot told the Sunday Times, “We can’t be sure, so we’re going to test it.”
A highly effective COVID-19 vaccine from AstraZeneca can accelerate the rollout and administration of vaccines to people around the world, noting that the two-dose vaccine is modernized and developed by Pfizer / BioNtech mRNA vaccine-like ultra-cold storage. do not require.
The AstraZeneca vaccine requires refrigeration from 36 degrees to 46 degrees Fahrenheit and can be stored for at least six months.
The United States has entered into a contract with AstraZeneca for 300 million doses of their vaccine, beating the 200 million orders for the vaccine for Modern and Pfizer / BioNotech.
Read more: Deutsche Bank says you need to own these 10 telecom shares as the vaccine progresses to 2021 recovery for beaten-down areas